# reload+after+2024-01-23 15:39:58.063873
address1§60 Gracechurch Street
address2§6th Floor
city§London
zip§EC3V 0HR
country§United Kingdom
phone§44 1223 627222
website§https://www.nuformix.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
fullTimeEmployees§1
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Joanne M. Holland', 'age': 48, 'title': 'Consultant', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 66000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Daniel John Gooding', 'age': 49, 'title': 'Executive Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 396100, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Benjamin  Harber', 'title': 'Company Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.411
currency§GBp
exchange§LSE
quoteType§EQUITY
shortName§NUFORMIX PLC ORD 0.1P
longName§Nuformix plc
firstTradeDateEpochUtc§1450339200
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§8ac23986-26f2-3b2d-9470-953eff6608dc
recommendationKey§none
quickRatio§1.43
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
